181 related articles for article (PubMed ID: 37704069)
21. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
[TBL] [Abstract][Full Text] [Related]
22. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.
Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F
Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
24. An Antibody to Notch2 Reverses the Osteopenic Phenotype of Hajdu-Cheney Mutant Male Mice.
Canalis E; Sanjay A; Yu J; Zanotti S
Endocrinology; 2017 Apr; 158(4):730-742. PubMed ID: 28323963
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides.
Aghajan M; Guo S; Monia BP
Methods Mol Biol; 2017; 1639():127-138. PubMed ID: 28752452
[TBL] [Abstract][Full Text] [Related]
26. Activation of Nfatc2 in osteoblasts causes osteopenia.
Zanotti S; Canalis E
J Cell Physiol; 2015 Jul; 230(7):1689-95. PubMed ID: 25573264
[TBL] [Abstract][Full Text] [Related]
27. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
[TBL] [Abstract][Full Text] [Related]
28. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
[TBL] [Abstract][Full Text] [Related]
29. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
[TBL] [Abstract][Full Text] [Related]
30. Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor.
Scharner J; Qi S; Rigo F; Bennett CF; Krainer AR
Mol Ther Nucleic Acids; 2019 Jun; 16():313-325. PubMed ID: 30965276
[TBL] [Abstract][Full Text] [Related]
31. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Moore LR; Rajpal G; Dillingham IT; Qutob M; Blumenstein KG; Gattis D; Hung G; Kordasiewicz HB; Paulson HL; McLoughlin HS
Mol Ther Nucleic Acids; 2017 Jun; 7():200-210. PubMed ID: 28624196
[TBL] [Abstract][Full Text] [Related]
33. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept.
Rutten JW; Dauwerse HG; Peters DJ; Goldfarb A; Venselaar H; Haffner C; van Ommen GJ; Aartsma-Rus AM; Lesnik Oberstein SA
Brain; 2016 Apr; 139(Pt 4):1123-35. PubMed ID: 26912635
[TBL] [Abstract][Full Text] [Related]
35. Hajdu Cheney Mouse Mutants Exhibit Osteopenia, Increased Osteoclastogenesis, and Bone Resorption.
Canalis E; Schilling L; Yee SP; Lee SK; Zanotti S
J Biol Chem; 2016 Jan; 291(4):1538-1551. PubMed ID: 26627824
[TBL] [Abstract][Full Text] [Related]
36. Mesenchymal stem cells alleviate AQP-4-dependent glymphatic dysfunction and improve brain distribution of antisense oligonucleotides in BACHD mice.
Wu TT; Su FJ; Feng YQ; Liu B; Li MY; Liang FY; Li G; Li XJ; Zhang Y; Cai ZQ; Pei Z
Stem Cells; 2020 Feb; 38(2):218-230. PubMed ID: 31648394
[TBL] [Abstract][Full Text] [Related]
37. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
[TBL] [Abstract][Full Text] [Related]
38. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
Uemura Y; Hagiwara K; Kobayashi K
PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
[TBL] [Abstract][Full Text] [Related]
39. Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations.
Huang L; Aghajan M; Quesenberry T; Low A; Murray SF; Monia BP; Guo S
Nucleic Acid Ther; 2019 Aug; 29(4):175-186. PubMed ID: 31070517
[TBL] [Abstract][Full Text] [Related]
40. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
